Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b/4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s425, 2024. DOI: 10.25251/skin.8.supp.425. Disponível em: https://skin.dermsquared.com/skin/article/view/3101. Acesso em: 19 may. 2025.